Compound Research Guide

CBC, explained simply with PubMed links

This page translates CBC research into plain English: what scientists studied, what kind of evidence exists, where the source links are strong or limited, and which PubMed records support each bucket.

Launch set page

Read Evidence Overview Open Source Table

83research sources

9evidence buckets

PubMedlinked references

What this page is

A plain-English research page about CBC. It explains what researchers studied and links the PubMed or DOI sources.

How to use it

Read the overview first. If a sentence matters to you, open the PubMed link or source table below it.

Important limit

This page is education, not medical advice, dosing advice, or a recommendation to use cannabinoids.

Evidence Rows 112

Traceable statements carried into the source table.

Human Evidence 3

Rows where human participants, patients, or clinical evidence are visible.

Mechanisms 35

Biology, target, enzyme, receptor, or pharmacology rows.

Safety / Limits 24

Safety, tolerability, uncertainty, or insufficient-evidence context.

Evidence Overview

CBC has research behind it, but the bucket matters.

This page currently indexes 83 research sources across 9 evidence bucket(s). Read it as a map of what researchers have studied, not as a single bottom-line instruction. PMID 21749363

Human evidence 3 evidence rows

Human studies are separated from preclinical and mechanistic evidence so a reader can see where people were actually studied. PMID 21749363

Mechanisms 35 evidence rows

Mechanistic rows explain biological plausibility, receptor activity, enzyme activity, or pharmacology; they do not automatically prove an outcome in people. PMID 21749363

Safety and limits 24 evidence rows

Safety, tolerability, product quality, impairment, interactions, and higher-risk contexts stay visible instead of being treated as footnotes. PMID 21749363

Evidence Buckets

What the CBC research is usually about

Jump to source-backed table

receptor, transporter, target, metabolic, or pharmacology mechanisms

CBC appears in rows about receptor, transporter, target, metabolic, or pharmacology mechanisms mechanisms. It currently draws from 26 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 21749363

Safety, tolerability, adverse events, impairment, toxicity, and formulation concerns

CBC appears in rows studying Safety, tolerability, adverse events, impairment, toxicity, and formulation concerns. It currently draws from 21 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 42163693

Skin and inflammatory dermatology

CBC appears in rows studying Skin and inflammatory dermatology. It currently draws from 21 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 42163693

Pain-related outcomes

CBC appears in rows studying Pain-related outcomes. It currently draws from 17 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 21749363

neurobehavioral, mood, neural stem cell, or neurogenesis outcomes

CBC appears in rows studying neurobehavioral, mood, neural stem cell, or neurogenesis outcomes. It currently draws from 12 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41680865

Inflammation-related outcomes

CBC appears in rows studying Inflammation-related outcomes. It currently draws from 9 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 21749363

Reader Map

Evidence buckets before the source table

Grouped for readability

Bucket	Plain-English meaning	Evidence posture	Starting source
receptor, transporter, target, metabolic, or pharmacology mechanisms	Grouped source-backed rows focused on receptor, transporter, target, metabolic, or pharmacology mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (16), mechanistic or pharmacological (10)	PMID 21749363
Safety, tolerability, adverse events, impairment, toxicity, and formulation concerns	Grouped source-backed rows focused on Safety, tolerability, adverse events, impairment, toxicity, and formulation concerns, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (12), mechanistic or pharmacological (4), preclinical (3), preliminary human (2)	PMID 42163693
Skin and inflammatory dermatology	Grouped source-backed rows focused on Skin and inflammatory dermatology, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (11), mechanistic or pharmacological (6), preclinical (3), preliminary human (1)	PMID 42163693
Pain-related outcomes	Grouped source-backed rows focused on Pain-related outcomes, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (3), mechanistic or pharmacological (9), preclinical (4), preliminary human (1)	PMID 21749363
neurobehavioral, mood, neural stem cell, or neurogenesis outcomes	Grouped source-backed rows focused on neurobehavioral, mood, neural stem cell, or neurogenesis outcomes, collapsed into one reader-facing bucket before the full source table.	Mechanistic and preclinical research summary: insufficient (5), mechanistic or pharmacological (6), preclinical (1)	PMID 41680865
Inflammation-related outcomes	Grouped source-backed rows focused on Inflammation-related outcomes, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (2), mechanistic or pharmacological (4), preclinical (2), preliminary human (1)	PMID 21749363
Safety, adverse events, impairment, and formulation concerns	Grouped source-backed rows focused on Safety, adverse events, impairment, and formulation concerns, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (1), preclinical (1), preliminary human (1)	PMID 37162192
receptor, target, or pharmacology mechanisms	Grouped source-backed rows focused on receptor, target, or pharmacology mechanisms, collapsed into one reader-facing bucket before the full source table.	Mapped evidence with interpretation limits: insufficient (2)	PMID 39808700

Safety Reading Notes

Read safety context beside the research guide.

The CBC source set includes safety-context rows around Safety, tolerability, adverse events, impairment, toxicity, and formulation concerns. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 21749363

Developed but mixed human research summary: insufficient (12), mechanistic or pharmacological (4), preclinical (3), preliminary human (2)

PubMed For Dummies Article

CBC Evidence Review: the long-form source walk-through

Quick read

CBC currently has 112 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 21749363
The evidence classes most visible in the row language are insufficient (53), mechanistic or pharmacological (39), preclinical (14), and preliminary human (6). PMID 41680865
The study-design language most visible in the row language is Animal study (38), Narrative or expert review (27), Cellular or in vitro study (20), and other mapped categories (5). PMID 37332213
The repeated topics are receptor, transporter, target, metabolic, or pharmacology mechanisms (26), safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe... (21), Skin and inflammatory dermatology (21), Pain-related outcomes (17), and other mapped categories (27), which tells the reader where to start opening PubMed and DOI links. PMID 41545891

Start with the research question

CBC is built from 112 source-backed evidence row(s) and 83 research source(s). The current evidence classes read as insufficient (53), mechanistic or pharmacological (39), preclinical (14), and preliminary human (6), and the study-design language most often reads as Animal study (38), Narrative or expert review (27), Cellular or in vitro study (20), and other mapped categories (5). PMID 21749363

The row-level question is not simply whether CBC is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are receptor, transporter, target, metabolic, or pharmacology mechanisms (26), safety, tolerability, adverse-event, impairment, toxicity, or formulation-spe... (21), Skin and inflammatory dermatology (21), Pain-related outcomes (17), and other mapped categories (27). PMID 42163693

Human evidence 3 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 41213439

Preclinical evidence 10 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 39921943

Mechanistic evidence 35 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 37764262

Limits and uncertainty 77 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 41256665

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 42139799

Where this page has the most source density

The largest bucket surfaced for this page is receptor, transporter, target, metabolic, or pharmacology mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Safety, tolerability, adverse events, impairment, toxicity, and formulation concerns, which gives readers another way to see what the literature repeatedly circles. PMID 21749363

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 42163693

Bucket chapters: what the literature is circling

receptor, transporter, target, metabolic, or pharmacology mechanisms

26 research sources 26 rows (657-682) Mechanistic research summary: insufficient (16), mechanistic or pharmacological (10)

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 21749363

Evidence row 657
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome... PMID 21749363
Evidence row 682
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 35399958

Safety, tolerability, adverse events, impairment, toxicity, and formulation concerns

21 research sources 21 rows (636-656) Developed but mixed human research summary: insufficient (12), mechanistic or pharmacological (4), preclinical (3), preliminary human (2)

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 42163693

Evidence row 636
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study d... PMID 42163693
Evidence row 656
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or... PMID 36854205

Skin and inflammatory dermatology

21 research sources 21 rows (700-720) Developed but mixed human research summary: insufficient (11), mechanistic or pharmacological (6), preclinical (3), preliminary human (1)

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 42163693

Evidence row 700
CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin,... PMID 42163693
Evidence row 720
CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory... PMID 7298870

Pain-related outcomes

17 research sources 17 rows (683-699) Developed but mixed human research summary: insufficient (3), mechanistic or pharmacological (9), preclinical (4), preliminary human (1)

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 21749363

Evidence row 683
CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 21749363
Evidence row 699
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 20942863

neurobehavioral, mood, neural stem cell, or neurogenesis outcomes

12 research sources 12 rows (721-732) Mechanistic and preclinical research summary: insufficient (5), mechanistic or pharmacological (6), preclinical (1)

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 41680865

Evidence row 721
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outco... PMID 41680865
Evidence row 732
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outco... PMID 23941747

Inflammation-related outcomes

9 research sources 9 rows (34-76) Developed but mixed human research summary: insufficient (2), mechanistic or pharmacological (4), preclinical (2), preliminary human (1)

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 21749363

Evidence row 34
CBC studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain... PMID 21749363
Evidence row 76
CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outco... PMID 42139799

Safety, adverse events, impairment, and formulation concerns

3 research sources 3 rows (169-173) Developed but mixed human research summary: insufficient (1), preclinical (1), preliminary human (1)

CBC appears in rows studying Safety, adverse events, impairment, and formulation concerns. It currently draws from 3 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 37162192

Evidence row 169
CBC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome... PMID 37162192
Evidence row 173
CBC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 33903673

receptor, target, or pharmacology mechanisms

2 research sources 2 rows (283-284) Mapped evidence with interpretation limits: insufficient (2)

CBC appears in rows studying receptor, target, or pharmacology mechanisms. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 39808700

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 39808700

Evidence row 283
CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 39808700
Evidence row 284
CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target,... PMID 35306000

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (3 row(s)), mechanistic evidence (35 row(s)), and safety/tolerability context (24 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 21749363

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 42163693

What this does and does not mean

It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 37162192
It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 40580638
It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 33903673

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 21749363

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 42163693

Source-reading checklist for CBC

Open the linked PubMed or DOI record. PMID 34078070
Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 39808700
Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 35306000
Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 42163693
Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 42057192

Source Notes

CBC source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

Evidence row 34
CBC studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes). PMID 21749363
Evidence class: insufficient; Study design: Narrative or expert review. Source: Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Evidence row 35
CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes). PMID 41680865
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.
Evidence row 36
CBC studied for Inflammation-related outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes). PMID 37332213
Evidence class: preclinical; Study design: Animal study. Source: The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation.
Evidence row 71
CBC studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes). PMID 41545891
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
Evidence row 72
CBC studied for Inflammation-related outcomes; evidence class: preliminary human (outcome measure: inflammation-related or pain-related outcomes). PMID 41213439
Evidence class: preliminary human. Source: Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study.
Evidence row 73
CBC studied for Inflammation-related outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes). PMID 39921943
Evidence class: preclinical; Study design: Animal study. Source: Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis.
Evidence row 74
CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-related or pain-related outcomes). PMID 37764262
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.
Evidence row 75
CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes). PMID 41256665
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.
Evidence row 76
CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes). PMID 42139799
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.
Evidence row 169
CBC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 37162192
Evidence class: preliminary human; Study design: Human clinical study. Source: The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial.
Evidence row 171
CBC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 40580638
Evidence class: preclinical; Study design: Animal study. Source: Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents.
Evidence row 173
CBC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 33903673
Evidence class: insufficient. Source: CBD, a precursor of THC in e-cigarettes.
Evidence row 251
CBC studied for Rare phytocannabinoids research topics; evidence class: insufficient (outcome measure: Rare phytocannabinoids research topics). PMID 34078070
Evidence class: insufficient. Source: Cannabichromene Racemization and Absolute Stereochemistry Based on a Cannabicyclol Analog.
Evidence row 283
CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms). PMID 39808700
Evidence class: insufficient. Source: Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae.
Evidence row 284
CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 35306000
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.
Evidence row 636
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42163693
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.
Evidence row 637
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42057192
Evidence class: preliminary human. Source: Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract.
Evidence row 638
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 38777605
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Potential of Cannabichromene (CBC) as a Therapeutic Agent.
Evidence row 639
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 40872492
Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
Evidence row 640
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 37630401
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.
Evidence row 641
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 37162192
Evidence class: preliminary human; Study design: Human clinical study. Source: The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial.
Evidence row 642
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (study design: Systematic review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 38229238
Evidence class: insufficient; Study design: Systematic review. Source: A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics.
Evidence row 643
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 40580638
Evidence class: preclinical; Study design: Animal study. Source: Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents.
Evidence row 644
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 37721989
Evidence class: preclinical; Study design: Animal study. Source: Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats.
Evidence row 645
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 33903673
Evidence class: insufficient. Source: CBD, a precursor of THC in e-cigarettes.
Evidence row 646
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 647
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 37414155
Evidence class: insufficient; Study design: Narrative or expert review. Source: Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy?
Evidence row 648
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42352060
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.
Evidence row 649
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 32628766
Evidence class: insufficient; Study design: Narrative or expert review. Source: Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era.
Evidence row 650
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 34622654
Evidence class: insufficient. Source: Cannabis Vaping: Existing and Emerging Modalities, Chemistry, and Pulmonary Toxicology.
Evidence row 651
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 33134364
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs.
Evidence row 652
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 37396845
Evidence class: insufficient; Study design: Animal study. Source: Pre-puberty cannabichromene exposure modulates reproductive function via alteration of spermatogenesis, steroidogenesis, and eNOS pathway metabolites.
Evidence row 653
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 39172143
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Genotoxicity of selected cannabinoids in human lymphoblastoid TK6 cells.
Evidence row 654
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 20619971
Evidence class: mechanistic or pharmacological. Source: Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.
Evidence row 655
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 41668212
Evidence class: mechanistic or pharmacological. Source: Mapping the research landscape of minor cannabinoids: a bibliometric analysis of research trends and hotspots.
Evidence row 656
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 36854205
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Development and validation of a fit-for-purpose UHPLC-ESI-MS/MS method for the quantitation of cannabinoids in different matrices.
Evidence row 657
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 21749363
Evidence class: insufficient; Study design: Narrative or expert review. Source: Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Evidence row 658
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 37764262
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.
Evidence row 659
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 38777605
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Potential of Cannabichromene (CBC) as a Therapeutic Agent.
Evidence row 660
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40872492
Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
Evidence row 661
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40006604
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacokinetics of Non-Psychotropic Phytocannabinoids.
Evidence row 662
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 35306000
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.
Evidence row 663
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40967679
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
Evidence row 664
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 28120231
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Pharmacology of Phytocannabinoids.
Evidence row 665
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 27435265
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids, inflammation, and fibrosis.
Evidence row 666
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 34838836
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis: Chemistry, extraction and therapeutic applications.
Evidence row 667
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40046175
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Pharmacology of Cannabinoids in Chronic Pain.
Evidence row 668
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40706771
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation.
Evidence row 669
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 36654096
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabigerol and cannabichromene in Cannabis sativa L.
Evidence row 670
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 39769302
Evidence class: insufficient; Study design: Animal study. Source: Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models.
Evidence row 671
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 31368508
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabichromene is a cannabinoid CB2 receptor agonist.
Evidence row 672
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40611782
Evidence class: insufficient; Study design: Animal study. Source: Effect of Quantitative Structural Properties and Drug Formulation in Four Cannabinoids (Cannabidiol, Cannabigerol, Cannabichromene, and Cannabinol) on Their Lymphatic Transport after Enteral Administration in Rats.
Evidence row 673
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 33395525
Evidence class: insufficient; Study design: Animal study. Source: Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome.
Evidence row 674
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40790027
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabichromene: integrative modulation of apoptosis, ferroptosis, and endocannabinoid signaling in pancreatic cancer therapy.
Evidence row 675
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 39137108
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene.
Evidence row 676
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 32315173
Evidence class: mechanistic or pharmacological. Source: The Oxidation of Phytocannabinoids to Cannabinoquinoids.
Evidence row 677
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 37023389
Evidence class: insufficient. Source: Natural Cannabichromene (CBC) Shows Distinct Scalemicity Grades and Enantiomeric Dominance in Cannabis sativa Strains.
Evidence row 678
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40271542
Evidence class: mechanistic or pharmacological. Source: Structure and Dynamics of Cannabinoid Binding to the GABAA Receptor.
Evidence row 679
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 23373571
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.
Evidence row 680
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 22300105
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice.
Evidence row 681
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 38950639
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Selected phytocannabinoids inhibit SN-38- and cytokine-evoked increases in epithelial permeability and improve intestinal barrier function in vitro.
Evidence row 682
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 35399958
Evidence class: mechanistic or pharmacological. Source: In silico discovery of non-psychoactive scaffolds in Cannabis halting SARS-CoV-2 host entry and replication machinery.
Evidence row 683
CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 21749363
Evidence class: insufficient; Study design: Narrative or expert review. Source: Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Evidence row 684
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 41680865
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.
Evidence row 685
CBC studied for Pain-related outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 37332213
Evidence class: preclinical; Study design: Animal study. Source: The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation.
Evidence row 686
CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 32899626
Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
Evidence row 687
CBC studied for Pain-related outcomes; evidence class: preliminary human (outcome measure: pain-related outcomes). PMID 41213439
Evidence class: preliminary human. Source: Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study.
Evidence row 688
CBC studied for Pain-related outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 39921943
Evidence class: preclinical; Study design: Animal study. Source: Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis.
Evidence row 689
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 41256665
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.
Evidence row 690
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 42139799
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.
Evidence row 691
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 33230154
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Evidence row 692
CBC studied for Pain-related outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 693
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (outcome measure: pain-related outcomes). PMID 19679411
Evidence class: mechanistic or pharmacological. Source: Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.
Evidence row 694
CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 40046175
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Pharmacology of Cannabinoids in Chronic Pain.
Evidence row 695
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 41794091
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabichromene attenuates fracture pain but impairs bone repair in a murine tibial fracture model.
Evidence row 696
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 41322279
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modulatory Effects of "Minor" Cannabinoids in an in vitro Model of Neuronal Hypersensitivity.
Evidence row 697
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 36551296
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Efficient Synthesis for Altering Side Chain Length on Cannabinoid Molecules and Their Effects in Chemotherapy and Chemotherapeutic Induced Neuropathic Pain.
Evidence row 698
CBC studied for Pain-related outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 38255191
Evidence class: preclinical; Study design: Animal study. Source: Antinociceptive Effects of Cannabichromene (CBC) in Mice: Insights from von Frey, Tail-Flick, Formalin, and Acetone Tests.
Evidence row 699
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 20942863
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.
Evidence row 700
CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 42163693
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.
Evidence row 701
CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 38777605
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Potential of Cannabichromene (CBC) as a Therapeutic Agent.
Evidence row 702
CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 37630401
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.
Evidence row 703
CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 40580638
Evidence class: preclinical; Study design: Animal study. Source: Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents.
Evidence row 704
CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 705
CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 38885660
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion.
Evidence row 706
CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 38889235
Evidence class: insufficient. Source: Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation.
Evidence row 707
CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 27094344
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.
Evidence row 708
CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 39769302
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models.
Evidence row 709
CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 39457041
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors.
Evidence row 710
CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 39596719
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy Against Streptococcus and Staphylococcus.
Evidence row 711
CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 35628241
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.
Evidence row 712
CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 37242431
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol and Minor Phytocannabinoids: A Preliminary Study to Assess Their Anti-Melanoma, Anti-Melanogenic, and Anti-Tyrosinase Properties.
Evidence row 713
CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 36769042
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway.
Evidence row 714
CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 35354487
Evidence class: insufficient. Source: Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: part 1 - continuous bivariate analysis.
Evidence row 715
CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 41202683
Evidence class: insufficient. Source: Design and synthesis of amphiphilic cannabichromene derivatives with antimicrobial potential.
Evidence row 716
CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 41121423
Evidence class: insufficient. Source: Targeting the antioxidant, antimicrobial and anti-inflammatory activity of non-psychotropic Cannabis sativa L.: a comparison with chemotype V.
Evidence row 717
CBC studied for Skin and inflammatory dermatology; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 41983582
Evidence class: preliminary human. Source: Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens.
Evidence row 718
CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 37514074
Evidence class: insufficient; Study design: Narrative or expert review. Source: Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review.
Evidence row 719
CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 38927152
Evidence class: insufficient. Source: Spent Material Extractives from Hemp Hydrodistillation as an Underexplored Source of Antimicrobial Cannabinoids.
Evidence row 720
CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 7298870
Evidence class: preclinical; Study design: Animal study. Source: Biological activity of cannabichromene, its homologs and isomers.
Evidence row 721
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 41680865
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.
Evidence row 722
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 39808700
Evidence class: insufficient. Source: Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae.
Evidence row 723
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 35306000
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.
Evidence row 724
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 37414155
Evidence class: insufficient; Study design: Narrative or expert review. Source: Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy?
Evidence row 725
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 41934896
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models.
Evidence row 726
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 36654096
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabigerol and cannabichromene in Cannabis sativa L.
Evidence row 727
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 39769302
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models.
Evidence row 728
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 36983897
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabichromene Induces Neuronal Differentiation in NSC-34 Cells: Insights from Transcriptomic Analysis.
Evidence row 729
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 35846999
Evidence class: insufficient; Study design: Narrative or expert review. Source: Antidepressant Effects of South African Plants: An Appraisal of Ethnobotanical Surveys, Ethnopharmacological and Phytochemical Studies.
Evidence row 730
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 40358684
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabichromene, a key non-psychotropic phytocannabinoid in treatment of major depressive disorder: in silico and in vivo explorations.
Evidence row 731
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 20332000
Evidence class: preclinical; Study design: Animal study. Source: Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.
Evidence row 732
CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes). PMID 23941747
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The effect of cannabichromene on adult neural stem/progenitor cells.

Source Trail

Source-backed evidence table and references

83 research sources

This section is the technical source layer under the overview. It keeps grouped evidence buckets, evidence rows, PubMed or DOI links, related pages, and references visible for audit and revision.

Plain-Language Summary

CBC has 112 source-backed evidence row(s) from 83 source(s). The current page should separate outcomes, mechanisms, formulation context, and safety signals.

Identity

Canonical name: cbc
Type: compound
Subtype: phytocannabinoid
Description: Controlled compound entry for future source discovery and claim review.

Evidence Snapshot

Evidence rows: 112
Sources: 83
Evidence classes: insufficient (53), mechanistic or pharmacological (39), preclinical (14), preliminary human (6)
Draft sections: human evidence (3), mechanistic evidence (35), preclinical evidence (10), safety (24), uncertainty (40)

Key Draft Sections

Human evidence: 3 evidence row(s).
Safety and tolerability: 24 evidence row(s).
Uncertainty and gaps: 40 evidence row(s).
Preclinical evidence: 10 evidence row(s).
Mechanistic evidence: 35 evidence row(s).

Studied Outcomes And Mechanisms

Subject	Relationship	Object Or Focus	Evidence Summary	Sources	Evidence Rows
CBC	studied for	Inflammation-related outcomes	Developed but mixed human research summary: insufficient (2), mechanistic or pharmacological (4), preclinical (2), preliminary human (1)	9	9 rows (34-76)
CBC	studied for	neurobehavioral, mood, neural stem cell, or neurogenesis outcomes	Mechanistic and preclinical research summary: insufficient (5), mechanistic or pharmacological (6), preclinical (1)	12	12 rows (721-732)
CBC	studied for	Pain-related outcomes	Developed but mixed human research summary: insufficient (3), mechanistic or pharmacological (9), preclinical (4), preliminary human (1)	17	17 rows (683-699)
CBC	studied for	Rare phytocannabinoids research topics	Mapped evidence with interpretation limits: insufficient (1)	1	251
CBC	studied for	receptor, target, or pharmacology mechanisms	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (283-284)
CBC	modulates	receptor, transporter, target, metabolic, or pharmacology mechanisms	Mechanistic research summary: insufficient (16), mechanistic or pharmacological (10)	26	26 rows (657-682)
CBC	studied for	safety, adverse-event, impairment, or formulation-specific concerns	Developed but mixed human research summary: insufficient (1), preclinical (1), preliminary human (1)	3	3 rows (169-173)
CBC	studied for	safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns	Developed but mixed human research summary: insufficient (12), mechanistic or pharmacological (4), preclinical (3), preliminary human (2)	21	21 rows (636-656)
CBC	studied for	Skin and inflammatory dermatology	Developed but mixed human research summary: insufficient (11), mechanistic or pharmacological (6), preclinical (3), preliminary human (1)	21	21 rows (700-720)

Source-Backed Evidence Table

Evidence Row	Statement	Source
34	CBC studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes).	Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.PubMed 21749363 DOI 10.1111/j.1476-5381.2011.01238.x
35	CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes).	Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.PubMed 41680865 DOI 10.1186/s42238-025-00384-7
36	CBC studied for Inflammation-related outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes).	The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation.PubMed 37332213 DOI 10.1097/sap.0000000000003547
71	CBC studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes).	Therapeutic potential of acidic cannabinoids: an update.PubMed 41545891 DOI 10.1186/s42238-026-00387-y
72	CBC studied for Inflammation-related outcomes; evidence class: preliminary human (outcome measure: inflammation-related or pain-related outcomes).	Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study.PubMed 41213439 DOI 10.1016/j.jep.2025.120856
73	CBC studied for Inflammation-related outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes).	Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis.PubMed 39921943 DOI 10.1016/j.jpet.2025.103389
74	CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: inflammation-related or pain-related outcomes).	Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.PubMed 37764262 DOI 10.3390/molecules28186487
75	CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes).	Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.PubMed 41256665 DOI 10.1101/2025.10.02.680148
76	CBC studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or pain-related outcomes).	Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.PubMed 42139799 DOI 10.1016/j.jpet.2026.104901
169	CBC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial.PubMed 37162192 DOI 10.1080/27697061.2023.2203221
171	CBC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents.PubMed 40580638 DOI 10.1016/j.ejmech.2025.117888
173	CBC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	CBD, a precursor of THC in e-cigarettes.PubMed 33903673 DOI 10.1038/s41598-021-88389-z
251	CBC studied for Rare phytocannabinoids research topics; evidence class: insufficient (outcome measure: Rare phytocannabinoids research topics).	Cannabichromene Racemization and Absolute Stereochemistry Based on a Cannabicyclol Analog.PubMed 34078070 DOI 10.1021/acs.joc.1c00451
283	CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, target, or pharmacology mechanisms).	Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae.PubMed 39808700 DOI 10.1021/acssynbio.4c00721
284	CBC studied for receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms).	In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.PubMed 35306000 DOI 10.1016/j.ejphar.2022.174836
636	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.PubMed 42163693 DOI 10.2174/0109298673390667251201115054
637	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract.PubMed 42057192 DOI 10.1186/s42238-026-00432-w
638	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	The Potential of Cannabichromene (CBC) as a Therapeutic Agent.PubMed 38777605 DOI 10.1124/jpet.124.002166
639	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.PubMed 40872492 DOI 10.3390/ph18081101
640	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.PubMed 37630401 DOI 10.3390/molecules28166149
641	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial.PubMed 37162192 DOI 10.1080/27697061.2023.2203221
642	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (study design: Systematic review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics.PubMed 38229238 DOI 10.1002/dta.3628
643	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents.PubMed 40580638 DOI 10.1016/j.ejmech.2025.117888
644	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats.PubMed 37721989 DOI 10.1089/can.2023.0049
645	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	CBD, a precursor of THC in e-cigarettes.PubMed 33903673 DOI 10.1038/s41598-021-88389-z
646	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
647	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy?PubMed 37414155 DOI 10.1016/j.arr.2023.101998
648	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.PubMed 42352060 DOI 10.3390/antiox15060754
649	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era.PubMed 32628766 DOI 10.1093/clinchem/hvaa113
650	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Cannabis Vaping: Existing and Emerging Modalities, Chemistry, and Pulmonary Toxicology.PubMed 34622654 DOI 10.1021/acs.chemrestox.1c00290
651	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs.PubMed 33134364 DOI 10.3389/fvets.2020.583404
652	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Pre-puberty cannabichromene exposure modulates reproductive function via alteration of spermatogenesis, steroidogenesis, and eNOS pathway metabolites.PubMed 37396845 DOI 10.1016/j.toxrep.2023.06.001
653	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Genotoxicity of selected cannabinoids in human lymphoblastoid TK6 cells.PubMed 39172143 DOI 10.1007/s00204-024-03826-y
654	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.PubMed 20619971 DOI 10.1016/j.drugalcdep.2010.05.019
655	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Mapping the research landscape of minor cannabinoids: a bibliometric analysis of research trends and hotspots.PubMed 41668212 DOI 10.1186/s42238-026-00402-2
656	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Development and validation of a fit-for-purpose UHPLC-ESI-MS/MS method for the quantitation of cannabinoids in different matrices.PubMed 36854205 DOI 10.1016/j.jchromb.2023.123629
657	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.PubMed 21749363 DOI 10.1111/j.1476-5381.2011.01238.x
658	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.PubMed 37764262 DOI 10.3390/molecules28186487
659	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	The Potential of Cannabichromene (CBC) as a Therapeutic Agent.PubMed 38777605 DOI 10.1124/jpet.124.002166
660	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.PubMed 40872492 DOI 10.3390/ph18081101
661	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Pharmacokinetics of Non-Psychotropic Phytocannabinoids.PubMed 40006604 DOI 10.3390/pharmaceutics17020236
662	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.PubMed 35306000 DOI 10.1016/j.ejphar.2022.174836
663	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
664	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Molecular Pharmacology of Phytocannabinoids.PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
665	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Cannabinoids, inflammation, and fibrosis.PubMed 27435265 DOI 10.1096/fj.201600646r
666	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Cannabis: Chemistry, extraction and therapeutic applications.PubMed 34838836 DOI 10.1016/j.chemosphere.2021.133012
667	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	The Pharmacology of Cannabinoids in Chronic Pain.PubMed 40046175 DOI 10.1159/000543813
668	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation.PubMed 40706771 DOI 10.1016/j.reprotox.2025.109006
669	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Cannabigerol and cannabichromene in Cannabis sativa L.PubMed 36654096 DOI 10.2478/acph-2021-0021
670	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models.PubMed 39769302 DOI 10.3390/ijms252413539
671	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Cannabichromene is a cannabinoid CB2 receptor agonist.PubMed 31368508 DOI 10.1111/bph.14815
672	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Effect of Quantitative Structural Properties and Drug Formulation in Four Cannabinoids (Cannabidiol, Cannabigerol, Cannabichromene, and Cannabinol) on Their Lymphatic Transport after Enteral Administration in Rats.PubMed 40611782 DOI 10.1021/acs.molpharmaceut.4c01357
673	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome.PubMed 33395525 DOI 10.1021/acschemneuro.0c00677
674	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Cannabichromene: integrative modulation of apoptosis, ferroptosis, and endocannabinoid signaling in pancreatic cancer therapy.PubMed 40790027 DOI 10.1038/s41420-025-02674-8
675	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene.PubMed 39137108 DOI 10.1089/can.2023.0212
676	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	The Oxidation of Phytocannabinoids to Cannabinoquinoids.PubMed 32315173 DOI 10.1021/acs.jnatprod.9b01284
677	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Natural Cannabichromene (CBC) Shows Distinct Scalemicity Grades and Enantiomeric Dominance in Cannabis sativa Strains.PubMed 37023389 DOI 10.1021/acs.jnatprod.2c01139
678	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Structure and Dynamics of Cannabinoid Binding to the GABAA Receptor.PubMed 40271542 DOI 10.1002/prot.26831
679	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.PubMed 23373571 DOI 10.1111/bph.12120
680	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice.PubMed 22300105 DOI 10.1111/j.1476-5381.2012.01879.x
681	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Selected phytocannabinoids inhibit SN-38- and cytokine-evoked increases in epithelial permeability and improve intestinal barrier function in vitro.PubMed 38950639 DOI 10.1016/j.tiv.2024.105888
682	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	In silico discovery of non-psychoactive scaffolds in Cannabis halting SARS-CoV-2 host entry and replication machinery.PubMed 35399958 DOI 10.2217/fvl-2021-0309
683	CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes).	Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.PubMed 21749363 DOI 10.1111/j.1476-5381.2011.01238.x
684	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.PubMed 41680865 DOI 10.1186/s42238-025-00384-7
685	CBC studied for Pain-related outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation.PubMed 37332213 DOI 10.1097/sap.0000000000003547
686	CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes).	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
687	CBC studied for Pain-related outcomes; evidence class: preliminary human (outcome measure: pain-related outcomes).	Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study.PubMed 41213439 DOI 10.1016/j.jep.2025.120856
688	CBC studied for Pain-related outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis.PubMed 39921943 DOI 10.1016/j.jpet.2025.103389
689	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.PubMed 41256665 DOI 10.1101/2025.10.02.680148
690	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.PubMed 42139799 DOI 10.1016/j.jpet.2026.104901
691	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
692	CBC studied for Pain-related outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
693	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (outcome measure: pain-related outcomes).	Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.PubMed 19679411 DOI 10.1016/j.drugalcdep.2009.06.009
694	CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes).	The Pharmacology of Cannabinoids in Chronic Pain.PubMed 40046175 DOI 10.1159/000543813
695	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Cannabichromene attenuates fracture pain but impairs bone repair in a murine tibial fracture model.PubMed 41794091 DOI 10.1016/j.bone.2026.117850
696	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Modulatory Effects of "Minor" Cannabinoids in an in vitro Model of Neuronal Hypersensitivity.PubMed 41322279 DOI 10.2147/jpr.s547613
697	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Efficient Synthesis for Altering Side Chain Length on Cannabinoid Molecules and Their Effects in Chemotherapy and Chemotherapeutic Induced Neuropathic Pain.PubMed 36551296 DOI 10.3390/biom12121869
698	CBC studied for Pain-related outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Antinociceptive Effects of Cannabichromene (CBC) in Mice: Insights from von Frey, Tail-Flick, Formalin, and Acetone Tests.PubMed 38255191 DOI 10.3390/biomedicines12010083
699	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.PubMed 20942863 DOI 10.1111/j.1476-5381.2010.01063.x
700	CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.PubMed 42163693 DOI 10.2174/0109298673390667251201115054
701	CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	The Potential of Cannabichromene (CBC) as a Therapeutic Agent.PubMed 38777605 DOI 10.1124/jpet.124.002166
702	CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.PubMed 37630401 DOI 10.3390/molecules28166149
703	CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents.PubMed 40580638 DOI 10.1016/j.ejmech.2025.117888
704	CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
705	CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion.PubMed 38885660 DOI 10.1055/a-2320-8822
706	CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation.PubMed 38889235 DOI 10.1021/acs.jnatprod.4c00212
707	CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.PubMed 27094344 DOI 10.1111/exd.13042
708	CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models.PubMed 39769302 DOI 10.3390/ijms252413539
709	CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors.PubMed 39457041 DOI 10.3390/ijms252011258
710	CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy Against Streptococcus and Staphylococcus.PubMed 39596719 DOI 10.3390/antibiotics13111023
711	CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.PubMed 35628241 DOI 10.3390/ijms23105430
712	CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Cannabidiol and Minor Phytocannabinoids: A Preliminary Study to Assess Their Anti-Melanoma, Anti-Melanogenic, and Anti-Tyrosinase Properties.PubMed 37242431 DOI 10.3390/ph16050648
713	CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway.PubMed 36769042 DOI 10.3390/ijms24032721
714	CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: part 1 - continuous bivariate analysis.PubMed 35354487 DOI 10.1186/s13690-022-00811-8
715	CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Design and synthesis of amphiphilic cannabichromene derivatives with antimicrobial potential.PubMed 41202683 DOI 10.1016/j.bioorg.2025.109184
716	CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Targeting the antioxidant, antimicrobial and anti-inflammatory activity of non-psychotropic Cannabis sativa L.: a comparison with chemotype V.PubMed 41121423 DOI 10.1186/s42238-025-00336-1
717	CBC studied for Skin and inflammatory dermatology; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens.PubMed 41983582 DOI 10.1093/jambio/lxag092
718	CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review.PubMed 37514074 DOI 10.3390/pharmaceutics15071889
719	CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Spent Material Extractives from Hemp Hydrodistillation as an Underexplored Source of Antimicrobial Cannabinoids.PubMed 38927152 DOI 10.3390/antibiotics13060485
720	CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Biological activity of cannabichromene, its homologs and isomers.PubMed 7298870 DOI 10.1002/j.1552-4604.1981.tb02606.x
721	CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes).	Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.PubMed 41680865 DOI 10.1186/s42238-025-00384-7
722	CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes).	Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae.PubMed 39808700 DOI 10.1021/acssynbio.4c00721
723	CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes).	In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.PubMed 35306000 DOI 10.1016/j.ejphar.2022.174836
724	CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes).	Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy?PubMed 37414155 DOI 10.1016/j.arr.2023.101998
725	CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes).	Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models.PubMed 41934896 DOI 10.1016/j.biopha.2026.119298
726	CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes).	Cannabigerol and cannabichromene in Cannabis sativa L.PubMed 36654096 DOI 10.2478/acph-2021-0021
727	CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes).	Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models.PubMed 39769302 DOI 10.3390/ijms252413539
728	CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes).	Cannabichromene Induces Neuronal Differentiation in NSC-34 Cells: Insights from Transcriptomic Analysis.PubMed 36983897 DOI 10.3390/life13030742
729	CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes).	Antidepressant Effects of South African Plants: An Appraisal of Ethnobotanical Surveys, Ethnopharmacological and Phytochemical Studies.PubMed 35846999 DOI 10.3389/fphar.2022.895286
730	CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes).	Cannabichromene, a key non-psychotropic phytocannabinoid in treatment of major depressive disorder: in silico and in vivo explorations.PubMed 40358684 DOI 10.1007/s00210-025-04236-2
731	CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes).	Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.PubMed 20332000 DOI 10.1016/j.pbb.2010.03.004
732	CBC studied for neurobehavioral, mood, neural stem cell, or neurogenesis outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: neurobehavioral, mood, neural stem cell, or neurogenesis outcomes).	The effect of cannabichromene on adult neural stem/progenitor cells.PubMed 23941747 DOI 10.1016/j.neuint.2013.08.002

Inflammation-related outcomes
Pain-related outcomes
Skin and inflammatory dermatology

References

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.PubMed 21749363 DOI 10.1111/j.1476-5381.2011.01238.x
Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.PubMed 41680865 DOI 10.1186/s42238-025-00384-7
The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation.PubMed 37332213 DOI 10.1097/sap.0000000000003547
Therapeutic potential of acidic cannabinoids: an update.PubMed 41545891 DOI 10.1186/s42238-026-00387-y
Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study.PubMed 41213439 DOI 10.1016/j.jep.2025.120856
Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis.PubMed 39921943 DOI 10.1016/j.jpet.2025.103389
Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.PubMed 37764262 DOI 10.3390/molecules28186487
Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.PubMed 41256665 DOI 10.1101/2025.10.02.680148
Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.PubMed 42139799 DOI 10.1016/j.jpet.2026.104901
The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial.PubMed 37162192 DOI 10.1080/27697061.2023.2203221
Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents.PubMed 40580638 DOI 10.1016/j.ejmech.2025.117888
CBD, a precursor of THC in e-cigarettes.PubMed 33903673 DOI 10.1038/s41598-021-88389-z
Cannabichromene Racemization and Absolute Stereochemistry Based on a Cannabicyclol Analog.PubMed 34078070 DOI 10.1021/acs.joc.1c00451
Enhancing Cannabichromenic Acid Biosynthesis in Saccharomyces cerevisiae.PubMed 39808700 DOI 10.1021/acssynbio.4c00721
In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.PubMed 35306000 DOI 10.1016/j.ejphar.2022.174836
Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.PubMed 42163693 DOI 10.2174/0109298673390667251201115054
Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract.PubMed 42057192 DOI 10.1186/s42238-026-00432-w
The Potential of Cannabichromene (CBC) as a Therapeutic Agent.PubMed 38777605 DOI 10.1124/jpet.124.002166
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.PubMed 40872492 DOI 10.3390/ph18081101
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.PubMed 37630401 DOI 10.3390/molecules28166149
A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics.PubMed 38229238 DOI 10.1002/dta.3628
Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats.PubMed 37721989 DOI 10.1089/can.2023.0049
The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy?PubMed 37414155 DOI 10.1016/j.arr.2023.101998
Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.PubMed 42352060 DOI 10.3390/antiox15060754
Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era.PubMed 32628766 DOI 10.1093/clinchem/hvaa113
Cannabis Vaping: Existing and Emerging Modalities, Chemistry, and Pulmonary Toxicology.PubMed 34622654 DOI 10.1021/acs.chemrestox.1c00290
Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs.PubMed 33134364 DOI 10.3389/fvets.2020.583404
Pre-puberty cannabichromene exposure modulates reproductive function via alteration of spermatogenesis, steroidogenesis, and eNOS pathway metabolites.PubMed 37396845 DOI 10.1016/j.toxrep.2023.06.001
Genotoxicity of selected cannabinoids in human lymphoblastoid TK6 cells.PubMed 39172143 DOI 10.1007/s00204-024-03826-y
Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.PubMed 20619971 DOI 10.1016/j.drugalcdep.2010.05.019
Mapping the research landscape of minor cannabinoids: a bibliometric analysis of research trends and hotspots.PubMed 41668212 DOI 10.1186/s42238-026-00402-2
Development and validation of a fit-for-purpose UHPLC-ESI-MS/MS method for the quantitation of cannabinoids in different matrices.PubMed 36854205 DOI 10.1016/j.jchromb.2023.123629
Pharmacokinetics of Non-Psychotropic Phytocannabinoids.PubMed 40006604 DOI 10.3390/pharmaceutics17020236
Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
Molecular Pharmacology of Phytocannabinoids.PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
Cannabinoids, inflammation, and fibrosis.PubMed 27435265 DOI 10.1096/fj.201600646r
Cannabis: Chemistry, extraction and therapeutic applications.PubMed 34838836 DOI 10.1016/j.chemosphere.2021.133012
The Pharmacology of Cannabinoids in Chronic Pain.PubMed 40046175 DOI 10.1159/000543813
Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation.PubMed 40706771 DOI 10.1016/j.reprotox.2025.109006
Cannabigerol and cannabichromene in Cannabis sativa L.PubMed 36654096 DOI 10.2478/acph-2021-0021
Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models.PubMed 39769302 DOI 10.3390/ijms252413539
Cannabichromene is a cannabinoid CB2 receptor agonist.PubMed 31368508 DOI 10.1111/bph.14815
Effect of Quantitative Structural Properties and Drug Formulation in Four Cannabinoids (Cannabidiol, Cannabigerol, Cannabichromene, and Cannabinol) on Their Lymphatic Transport after Enteral Administration in Rats.PubMed 40611782 DOI 10.1021/acs.molpharmaceut.4c01357
Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome.PubMed 33395525 DOI 10.1021/acschemneuro.0c00677
Cannabichromene: integrative modulation of apoptosis, ferroptosis, and endocannabinoid signaling in pancreatic cancer therapy.PubMed 40790027 DOI 10.1038/s41420-025-02674-8
Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene.PubMed 39137108 DOI 10.1089/can.2023.0212
The Oxidation of Phytocannabinoids to Cannabinoquinoids.PubMed 32315173 DOI 10.1021/acs.jnatprod.9b01284
Natural Cannabichromene (CBC) Shows Distinct Scalemicity Grades and Enantiomeric Dominance in Cannabis sativa Strains.PubMed 37023389 DOI 10.1021/acs.jnatprod.2c01139
Structure and Dynamics of Cannabinoid Binding to the GABAA Receptor.PubMed 40271542 DOI 10.1002/prot.26831
The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.PubMed 23373571 DOI 10.1111/bph.12120
Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice.PubMed 22300105 DOI 10.1111/j.1476-5381.2012.01879.x
Selected phytocannabinoids inhibit SN-38- and cytokine-evoked increases in epithelial permeability and improve intestinal barrier function in vitro.PubMed 38950639 DOI 10.1016/j.tiv.2024.105888
In silico discovery of non-psychoactive scaffolds in Cannabis halting SARS-CoV-2 host entry and replication machinery.PubMed 35399958 DOI 10.2217/fvl-2021-0309
It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.PubMed 19679411 DOI 10.1016/j.drugalcdep.2009.06.009
Cannabichromene attenuates fracture pain but impairs bone repair in a murine tibial fracture model.PubMed 41794091 DOI 10.1016/j.bone.2026.117850
Modulatory Effects of "Minor" Cannabinoids in an in vitro Model of Neuronal Hypersensitivity.PubMed 41322279 DOI 10.2147/jpr.s547613
Efficient Synthesis for Altering Side Chain Length on Cannabinoid Molecules and Their Effects in Chemotherapy and Chemotherapeutic Induced Neuropathic Pain.PubMed 36551296 DOI 10.3390/biom12121869
Antinociceptive Effects of Cannabichromene (CBC) in Mice: Insights from von Frey, Tail-Flick, Formalin, and Acetone Tests.PubMed 38255191 DOI 10.3390/biomedicines12010083
Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.PubMed 20942863 DOI 10.1111/j.1476-5381.2010.01063.x
Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion.PubMed 38885660 DOI 10.1055/a-2320-8822
Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation.PubMed 38889235 DOI 10.1021/acs.jnatprod.4c00212
Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment.PubMed 27094344 DOI 10.1111/exd.13042
Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors.PubMed 39457041 DOI 10.3390/ijms252011258
Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy Against Streptococcus and Staphylococcus.PubMed 39596719 DOI 10.3390/antibiotics13111023
Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.PubMed 35628241 DOI 10.3390/ijms23105430
Cannabidiol and Minor Phytocannabinoids: A Preliminary Study to Assess Their Anti-Melanoma, Anti-Melanogenic, and Anti-Tyrosinase Properties.PubMed 37242431 DOI 10.3390/ph16050648
Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway.PubMed 36769042 DOI 10.3390/ijms24032721
Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: part 1 - continuous bivariate analysis.PubMed 35354487 DOI 10.1186/s13690-022-00811-8
Design and synthesis of amphiphilic cannabichromene derivatives with antimicrobial potential.PubMed 41202683 DOI 10.1016/j.bioorg.2025.109184
Targeting the antioxidant, antimicrobial and anti-inflammatory activity of non-psychotropic Cannabis sativa L.: a comparison with chemotype V.PubMed 41121423 DOI 10.1186/s42238-025-00336-1
Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens.PubMed 41983582 DOI 10.1093/jambio/lxag092
Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review.PubMed 37514074 DOI 10.3390/pharmaceutics15071889
Spent Material Extractives from Hemp Hydrodistillation as an Underexplored Source of Antimicrobial Cannabinoids.PubMed 38927152 DOI 10.3390/antibiotics13060485
Biological activity of cannabichromene, its homologs and isomers.PubMed 7298870 DOI 10.1002/j.1552-4604.1981.tb02606.x
Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models.PubMed 41934896 DOI 10.1016/j.biopha.2026.119298
Cannabichromene Induces Neuronal Differentiation in NSC-34 Cells: Insights from Transcriptomic Analysis.PubMed 36983897 DOI 10.3390/life13030742
Antidepressant Effects of South African Plants: An Appraisal of Ethnobotanical Surveys, Ethnopharmacological and Phytochemical Studies.PubMed 35846999 DOI 10.3389/fphar.2022.895286
Cannabichromene, a key non-psychotropic phytocannabinoid in treatment of major depressive disorder: in silico and in vivo explorations.PubMed 40358684 DOI 10.1007/s00210-025-04236-2
Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.PubMed 20332000 DOI 10.1016/j.pbb.2010.03.004
The effect of cannabichromene on adult neural stem/progenitor cells.PubMed 23941747 DOI 10.1016/j.neuint.2013.08.002

CBC has research behind it, but the bucket matters.

What the CBC research is usually about

receptor, transporter, target, metabolic, or pharmacology mechanisms

Safety, tolerability, adverse events, impairment, toxicity, and formulation concerns

Skin and inflammatory dermatology

Pain-related outcomes

neurobehavioral, mood, neural stem cell, or neurogenesis outcomes

Inflammation-related outcomes

Evidence buckets before the source table

Keep reading around this topic

Read safety context beside the research guide.

CBC Evidence Review: the long-form source walk-through

Start with the research question

Where this page has the most source density

Bucket chapters: what the literature is circling

receptor, transporter, target, metabolic, or pharmacology mechanisms

Safety, tolerability, adverse events, impairment, toxicity, and formulation concerns

Skin and inflammatory dermatology

Pain-related outcomes

neurobehavioral, mood, neural stem cell, or neurogenesis outcomes

Inflammation-related outcomes

Safety, adverse events, impairment, and formulation concerns

receptor, target, or pharmacology mechanisms

Human evidence, mechanisms, and safety are different lanes

What this does and does not mean

How to use the source table

Source-reading checklist for CBC

CBC source-by-source reading notes

Source-backed evidence table and references

Plain-Language Summary

Identity

Evidence Snapshot

Key Draft Sections

Studied Outcomes And Mechanisms

Source-Backed Evidence Table

Related Pages

References